Compare WYNN & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WYNN | ICLR |
|---|---|---|
| Founded | 2002 | 1990 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 7.1B |
| IPO Year | 2002 | 2001 |
| Metric | WYNN | ICLR |
|---|---|---|
| Price | $100.81 | $110.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 13 |
| Target Price | $144.43 | ★ $194.38 |
| AVG Volume (30 Days) | 1.9M | ★ 3.5M |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.14 | N/A |
| Revenue | ★ $6,717,660,000.00 | N/A |
| Revenue This Year | $6.32 | N/A |
| Revenue Next Year | $3.70 | N/A |
| P/E Ratio | $32.50 | ★ $12.91 |
| Revenue Growth | ★ 10.67 | N/A |
| 52 Week Low | $65.25 | $66.57 |
| 52 Week High | $134.72 | $211.00 |
| Indicator | WYNN | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 36.73 | 39.22 |
| Support Level | $82.63 | $66.57 |
| Resistance Level | $111.94 | $153.72 |
| Average True Range (ATR) | 3.84 | 5.36 |
| MACD | -0.73 | 3.35 |
| Stochastic Oscillator | 16.24 | 85.75 |
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, and Encore Boston Harbor in Massachusetts opened June 2019. We expect the company to continue to build nongaming attractions in Macao over the next few years. We model Wynn's managed integrated resort in the United Arab Emirates to open in 2027. The company also operates Wynn Interactive, a digital sports betting and iGaming platform, in a few states. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and the US, respectively. In 2024, both the US and Macao were each 50% of total EBITDA.
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.